Research
Why an exported American drug cannot simply come back
A prescription drug made in the United States and shipped abroad may be reimported by nobody except its own manufacturer. The one exception is emergency medical care, and it runs through a district office.
The rule is one sentence long
People often assume that a medication manufactured in the United States must be easy to bring back into it. The regulation says the opposite in a single sentence.
No prescription drug, or drug composed wholly or partly of insulin, that was manufactured in a state and exported from the United States may be reimported by anyone other than its manufacturer.
The identity of the importer is the whole test. Not the product's quality, not its labeling, not where it has been. Who is bringing it back.
That is why an American-made product offered from abroad is a different proposition from an American-made product bought here, even when it is the identical item.
What the rule is protecting
The reasoning is about the chain of custody rather than the molecule.
A drug that leaves the country stops being tracked by the domestic distribution system. Storage conditions, handling and ownership become unverifiable from inside.
Restricting reimportation to the manufacturer means the only party allowed to bring it back is the one that can identify what it originally shipped and to whom.
The rule does not assert that a reimported drug is unsafe. It removes the question by removing the route.
The one exception, and how narrow it is
There is a single stated exception, and it is not commercial.
The agency may grant permission to a person other than the manufacturer to reimport a prescription drug or insulin-containing drug if it determines that such reimportation is required for emergency medical care.
Two things about that clause. It requires a determination by the agency, so it is a permission rather than a status a party can claim.
And the standard is that reimportation is required for emergency medical care. Not convenient, not cheaper, not preferable. Required, and for an emergency.
The permission runs through a district office
The procedure is short and worth knowing because it shows the scale the exception operates at.
Applications for reimportation for emergency medical care are submitted to the director of the agency district office in the district where reimportation is sought.
And they are reviewed and approved or disapproved by each district office. The decision is made locally, case by case.
This is not a program with a registration or a general license. It is an application about a specific shipment, decided by the office covering the place it would arrive.
And there is an appeal
A separate section provides a route when a district office says no.
An appeal from an adverse decision involving insulin-containing drugs or human prescription drugs or biological products regulated by the drug center may be made to that center's compliance office.
An appeal involving human prescription biological products regulated by the biologics center goes to that center instead.
The split matters more than it looks. Which center regulates a product decides where the appeal goes, and that is a question about the product's regulatory category rather than about what it contains.
A neighboring rule people conflate with this one
The same part contains a restriction on who may sell, purchase or trade prescription drugs — a wholesale distribution rule that is frequently confused with the reimportation prohibition.
That restriction comes with a list of nine exclusions, and reading them shows how differently the two rules are built.
The exclusions cover purchases by a hospital or other health care entity from a group purchasing organization it belongs to, or from other member hospitals or entities. They cover transfers by a charitable organization to a nonprofit affiliate. And they cover transactions among hospitals or health care entities under common control.
They also cover transactions for emergency medical reasons, and the sale, purchase, trade or dispensing of a drug under a valid prescription.
The rest of the exclusions
Four more exclusions round out the list, and they are all about specific kinds of institution or product.
Transactions among hospitals or health care entities owned or operated by federal, state or local governmental units.
Blood or blood components intended for transfusion.
Certain transactions by a registered blood establishment that qualifies as a health care entity. Those cover drugs indicated for a bleeding or clotting disorder or anemia, approved blood collection containers, and blood derivatives including recombinant or synthetic forms. The exclusion is subject to conditions about what other services the establishment provides.
And equivalent transactions by a comprehensive hemophilia diagnostic treatment center receiving a federal grant and qualifying as a health care entity. Both of those last two carry the same rider: an establishment relying on the exclusion must satisfy all other requirements of the statute and the part applicable to a wholesale distributor or retail pharmacy.
Why the contrast is the useful part
The wholesale restriction is a rule with nine ways out, most of them describing institutions with their own oversight.
The reimportation prohibition has one way out, it requires an agency determination, and the standard is emergency medical care.
Reading them side by side shows what the drafters treated as a routine commercial question and what they treated as a border they did not want crossed.
A reader can use that directly. An offer that depends on a product having gone abroad and come back is depending on a route the regulation closes to everyone except the manufacturer.
What this does not settle
This is one rule in one part. Separate provisions govern personal importation, unapproved products, and imports of things that were never exported from here, and none of those were read for this article.
It also says nothing about any particular seller or shipment. The regulation describes who may reimport an exported American prescription drug, and this describes the regulation.
The narrow point is the durable one. Manufactured in America is not by itself an import argument, because the rule turns on who is bringing it back rather than on where it was made.
Key takeaways
- An exported American prescription drug may be reimported only by its own manufacturer.
- The test is who is importing, not the condition, labeling or origin of the product.
- The single exception requires an agency determination that reimportation is needed for emergency medical care.
- Applications go to the district office covering the place of reimportation, which decides them.
- Appeals route to the drug center or the biologics center depending on the product's category.
- The neighboring wholesale distribution restriction has nine exclusions; this prohibition has one.
Frequently asked questions
Can anyone reimport an American-made prescription drug?
No. The regulation states that no prescription drug, or drug composed wholly or partly of insulin, may be reimported by anyone other than its manufacturer. That applies to one manufactured in a state and exported from the United States. The test is the identity of the importer, not the condition of the product.
Is there any exception to the reimportation ban?
One. The agency may grant permission to a person other than the manufacturer if it determines that the reimportation is required for emergency medical care. It is a permission granted on a determination, not a status a party can claim, and the standard is that the reimportation is required rather than merely preferable.
How is emergency reimportation permission obtained?
By application to the director of the agency district office in the district where reimportation is sought. Each district office reviews and approves or disapproves those applications. An adverse decision can be appealed, to the drug center's compliance office or to the biologics center, depending on which regulates the product.
Does the same part restrict who can buy and sell prescription drugs domestically?
Yes, and that restriction is separate. It carries nine exclusions. They cover group purchasing organizations, charitable affiliates, entities under common control, emergency medical reasons, and dispensing under a valid prescription. They also cover government-operated entities, blood and blood components, certain registered blood establishments, and comprehensive hemophilia diagnostic treatment centers.
Does "made in America" help an overseas offer?
Not under this rule. The prohibition applies specifically to a prescription drug manufactured in a state and exported from the United States, and closes reimportation to everyone except the manufacturer. Where the product was made is what puts it inside the rule, not what gets it out.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- 21 CFR 203.10, Restrictions on reimportation — Electronic Code of Federal Regulations, title 21, August 2026
- 21 CFR 203.11, Applications for reimportation to provide emergency medical care — Electronic Code of Federal Regulations, title 21, April 2004
- 21 CFR 203.12, An appeal from an adverse decision by the district office — Electronic Code of Federal Regulations, title 21, April 2015
- 21 CFR 203.22, Exclusions — Electronic Code of Federal Regulations, title 21, October 2008